A Deeper Look at Neuromyelitis Optica Spectrum Disorder: A Glimpse Onto the Clinic Floor with Specialists
Though neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still causes it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and even harmful treatment. The emergence of similarly presenting MOG antibody disease as its own entity has further complicated the picture. Thankfully, FDA-approved targeted therapies have recently become available to treat NMOSD. But such rapid advancement alongside continually evolving understanding of serotypes, biomarkers, and neuroimaging signs has created an environment prone to knowledge and performance deficiencies. Due to the long-term consequences of repeated attacks, early recognition and optimization of clinical decisions is critical. This symposium, originally held in conjunction with the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, is designed to enable clinicians to directly compare their practices with those of surveyed experts, allowing learners to visualize how their decisions may differ from recommended strategies and, if needed, correct for deviations in their approaches.
The target audience for this CME initiative includes neurodegenerative disease specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the diagnosis and long-term management of patients with NMOSD.
Upon completion of the educational activity, participants should be able to:
- Compare and contrast your diagnostic and management approaches for patients with diverse presentations of NMOSD to those of specialists and affirm or modify your decision-making accordingly
- Distinguish key clinical and radiological features that distinguish NMOSD alongside rising tools for prognosis in order to more rapidly diagnose and tailor clinical strategies to individuals with both AQP4-IgG seropositive and seronegative presentations of the disease
- Assess clinical investigator perspectives on the optimal management of acute attacks, including appropriate corticosteroid and plasma exchange protocols, and subsequent follow-up in order to maximize acute recovery and formulate effective management plans long term
- Describe the roles of, most recent data evaluating, and clinical experience utilizing agents specifically designed to treat NMOSD to integrate them more effectively into practice and maximize patient outcomes
Associate Professor of Neurosciences
UC San Diego Health
San Diego, CA
This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC.
This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Efficient, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Conflicts of Interest Disclosure Policy
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Efficient, LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Planners' and Managers' Disclosure
All additional planning committee members, staff and reviewers of Efficient LLC and Purdue University College of Pharmacy have no relationships to disclose.
Dr. Weinshenker reported the following financial relationships:
- Consulting Fees: Genentech/Roche, Horizon/VielaBio, Mitsubishi-Tanabe
- Speaking Fees: Genentech/Roche, Mitsubishi-Tanabe
- Chair, Adjudication Committee: Horizon/VielaBio, UCB Biosciences
- Royalty: RSR Ltd.
Dr. Bennett reported the following financial relationships:
- Consulting Fees: Alexion, Antigenomycs, BeiGene, Chugai, Genentech/Roche, Horizon, Mitsubishi-Tanabe, Reistone-Bio
- Grants/Research Support: Alexion, Mallinckrodt, Novartis
- Advisory Board: Chugai, Genentech/Roche, Horizon, TG Therapeutics
Dr. Graves reported the following financial relationships:
- Consulting Fees: Genentech, Novartis
- Grants/Research Support: EMD Serono, Sanofi
Disclosure of Unlabeled Use/Disclaimer
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Genentech, a member of the Roche Group.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance